Related Experiment Video

Updated: Aug 23, 2025

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

38.0K

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib

Maya Gross1, Ryan J Spencer2

  • 1Department of Obstetrics and Gynecology, University of Wisconsin-Madison School of Medicine and Public Health, USA.

Case Reports in Obstetrics and Gynecology
|November 4, 2022
PubMed

Insights

Olaparib, a PARP inhibitor, shows promise for recurrent metastatic clear cell cervical cancer in a patient with a BRCA2 mutation. This novel single-agent therapy demonstrated a durable response, offering a potential new treatment avenue.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Recurrent cervical cancer has a poor prognosis with limited effective treatment options.
  • Current standards of care offer minimal survival benefits for advanced disease.
  • Only one targeted therapy is currently FDA-approved for recurrent cervical cancer.

Observation:

  • A patient with recurrent metastatic clear cell cervical cancer and a somatic BRCA2 mutation was treated with olaparib.
  • Olaparib was administered as a single-agent therapy.
  • The patient experienced a significant and durable response to the treatment.

Findings:

  • The patient achieved stable disease without progression for 14 months on olaparib monotherapy.
  • This indicates a positive response to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibition in this specific context.
  • The treatment was well-tolerated, allowing for extended use.

Implications:

  • This case highlights the potential of olaparib as a single-agent therapy for recurrent metastatic clear cell cervical cancer.
  • Targeting DNA repair pathways, such as through PARP inhibition, may be effective in BRCA2-mutated cervical cancers.
  • Further investigation into PARP inhibitors for this patient population is warranted.

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.8K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K